Lenacapavir (Sunlenca)

All References

• Bekerman E, Yant SR, VanderVeen LA, et al. Long-acting lenacapavir acts as an effective pre-exposure prophylaxis in a rectal SHIV challenge macaque model. J Clin Invest. 2023 Jun 29. Online ahead of print.
  [PubMed Abstract]
• Bester SM, Adu-Ampratwum D, Annamalai AS, et al. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir. mBio. 2022;13:e0180422.
  [PubMed Abstract]
• Chatzidaki I, Curteis T, Luedke H, et al. Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus. Value Health. 2023;26:810-22.
  [PubMed Abstract]
• Cilento ME, Ong YT, Tedbury PR, Sarafianos SG. Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations. Viruses. 2022;14:(6):1202.
  [PubMed Abstract]
• Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022;17:15-21.
  [PubMed Abstract]
• Gupta SK, Berhe M, Crofoot G, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Lancet HIV. 2023;10:e15-e23.
  [PubMed Abstract]
• Highland CM, Tan A, Ricaña CL, Briggs JAG, Dick RA. Structural insights into HIV-1 polyanion-dependent capsid lattice formation revealed by single particle cryo-EM. Proc Natl Acad Sci U S A. 2023 May 2;120:e2220545120.
  [PubMed Abstract]
• Margot N, Ram R, Rhee M, Callebaut C. Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes. Antimicrob Agents Chemother. 2021;65(3):e02057-20.
  [PubMed Abstract]
• Margot N, Vanderveen L, Naik V, et al. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study. J Antimicrob Chemother. 2022;77:989-95.
  [PubMed Abstract]
• Margot NA, Naik V, VanderVeen L, et al. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir. J Infect Dis. 2022;226:1985-91.
  [PubMed Abstract]
• Marquis KA, Everett J, Cantu A, et al. The HIV-1 Capsid-Targeted Inhibitor GSK878 Alters Selection of Target Sites for HIV DNA Integration. AIDS Res Hum Retroviruses. 2023 Jun 7. Online ahead of print.
  [PubMed Abstract]
• Mushtaq A, Kazi F. Lenacapavir: a new treatment of resistant HIV-1 infections. Lancet Infect Dis. 2023;23:286.
  [PubMed Abstract]
• Nka AD, Bouba Y, Teto G, et al. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals. J Antimicrob Chemother. 2022;78:272-5.
  [PubMed Abstract]
• Orkin C. Lenacapavir in first-line therapy. Lancet HIV. 2023;10:e2-e3.
  [PubMed Abstract]
• Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022;386:1793-1803.
  [PubMed Abstract]
• Tailor MW, Chahine EB, Koren D, Sherman EM. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV. Ann Pharmacother. 2023:10600280231171375.
  [PubMed Abstract]